Literature DB >> 26141208

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

C Zhou1, Y L Wu2, G Chen3, J Feng4, X-Q Liu5, C Wang6, S Zhang7, J Wang8, S Zhou9, S Ren9, S Lu10, L Zhang22, C Hu13, C Hu13, Y Luo14, L Chen15, M Ye16, J Huang17, X Zhi18, Y Zhang19, Q Xiu20, J Ma21, L Zhang22, C You23.   

Abstract

BACKGROUND: The OPTIMAL study was the first study to compare efficacy and tolerability of the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus standard chemotherapy in first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). Findings from final overall survival (OS) analysis and assessment of post-study treatment impact are presented. PATIENTS AND METHODS: Of 165 randomised patients, 82 received erlotinib and 72 gemcitabine plus carboplatin. Final OS analyses were conducted when 70% of deaths had occurred in the intent-to-treat population. Subgroup OS was analysed by Cox proportional hazards model and included randomisation stratification factors and post-study treatments.
RESULTS: Median OS was similar between the erlotinib (22.8 months) and chemotherapy (27.2 months) arms with no significant between-group differences in the overall population [hazard ratio (HR), 1.19; 95% confidence interval (CI) 0.83-1.71; P = 0.2663], the exon 19 deletion subpopulation (HR, 1.52; 95% CI 0.91-2.52; P = 0.1037) or the exon 21 L858 mutation subpopulation (HR, 0.92; 95% CI 0.55-1.54; P = 0.7392). More patients in the erlotinib arm versus the chemotherapy arm did not receive any post-study treatment (36.6% versus 22.2%). Patients who received sequential combination of EGFR-TKI and chemotherapy had significantly improved OS compared with those who received EGFR-TKI or chemotherapy only (29.7 versus 20.7 or 11.2 months, respectively; P < 0.0001). OS was significantly shorter in patients who did not receive post-study treatments compared with those who received subsequent treatments in both arms.
CONCLUSION: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutant NSCLC patients, suggesting that erlotinib should be considered standard first-line treatment of EGFR mutant patients and EGFR-TKI treatment following first-line therapy also brings significant benefits to those patients. CLINICALTRIALSGOV IDENTIFIER: NCT00874419.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  EGFR mutations; chemotherapy; erlotinib; non-small-cell lung cancer; overall survival

Mesh:

Substances:

Year:  2015        PMID: 26141208     DOI: 10.1093/annonc/mdv276

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  168 in total

Review 1.  Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.

Authors:  Grainne M O'Kane; Natasha B Leighl
Journal:  Transl Lung Cancer Res       Date:  2016-12

2.  Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada.

Authors:  Yong-Jin Kim; Mark Oremus; Helen H Chen; Thomas McFarlane; Danielle Fearon; Susan Horton
Journal:  Pharmacoeconomics       Date:  2021-03-31       Impact factor: 4.981

Review 3.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

Review 4.  Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.

Authors:  Grainne M O'Kane; Natasha B Leighl
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

Review 5.  The changing landscape of clinical trial and approval processes in China.

Authors:  Qing Zhou; Xiao-Yuan Chen; Zhi-Min Yang; Yi-Long Wu
Journal:  Nat Rev Clin Oncol       Date:  2017-02-14       Impact factor: 66.675

6.  Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial.

Authors:  Kentaro Ito; Osamu Hataji
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 7.  Epidermal growth factor receptor first generation tyrosine-kinase inhibitors.

Authors:  Alex Martinez-Marti; Alejandro Navarro; Enriqueta Felip
Journal:  Transl Lung Cancer Res       Date:  2019-11

Review 8.  Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

Authors:  Saiama N Waqar; Philip D Bonomi; Ramaswamy Govindan; Fred R Hirsch; Gregory J Riely; Vassiliki Papadimitrakopoulou; Dickran Kazandjian; Sean Khozin; Erin Larkins; Dane J Dickson; Shakun Malik; Leora Horn; Andrea Ferris; Alice T Shaw; Pasi A Jänne; Tony S K Mok; Roy Herbst; Patricia Keegan; Richard Pazdur; Gideon M Blumenthal
Journal:  J Thorac Oncol       Date:  2016-07-09       Impact factor: 15.609

9.  Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?

Authors:  Tetsuya Mitsudomi; Yoshihisa Kobayashi
Journal:  Transl Lung Cancer Res       Date:  2016-08

10.  Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer.

Authors:  Gino In; Jeremy Mason; Sonia Lin; Paul K Newton; Peter Kuhn; Jorge Nieva
Journal:  Converg Sci Phys Oncol       Date:  2017-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.